Figure 1.
Kaplan–Meier overall survival from start of radiation therapy for all patients (a) and oropharynx patients (b) receiving concurrent high-dose cisplatin (green), 5-fluorouracil/carboplatin (blue), or cetuximab (red).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.